Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00201734
Status:
TERMINATED
Last Update Posted:
2016-09-23
First Post:
2005-09-12
Brief Title:
Capecitabine Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Sponsor:
Ohio State University Comprehensive Cancer Center
Organization:
Ohio State University Comprehensive Cancer Center
Study Overview
Official Title:
A Phase I Dose Escalation Study of Capecitabine Carboplatin and Weekly Paclitaxel and a Phase II Trial of the Same Combination in Patients With Adenocarcinoma of Unknown Primary
Status:
TERMINATED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to lack of funding provided for Phase II portion of trial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin
Detailed Description:
Rationale The combination of the chemotherapy drugs paclitaxel and carboplatin is one of the most common combination regimens used in clinical practice for cancer These agents are used for a variety of cancers The current study builds on previous research about treatment schedules for administering these agents to reduce toxicity and optimize efficacy The phase I and II portions of the current study combine paclitaxel and carboplatin with capecitabine in patients Researchers are seeking to identify the highest dose of capecitabine and paclitaxel in combination with carboplatin for this patient population as well as to gather information about preliminary efficacy
Purpose The phase I portion of this study will evaluate the maximum tolerated dose of capecitabine and paclitaxel in combination with carboplatin for patients The phase II portion of this study will assess the objective response rate in patients using the same treatment combination Toxicities will be closely measured in both phases of the study
Treatment Patients in this study will be given capecitabine carboplatin and paclitaxel Capecitabine will be given through oral pills Carboplatin and paclitaxel will be given through intravenous infusions Treatment drugs will be given on a four-week cycle Carboplatin will be administered on day 1 paclitaxel weekly for the first 3 weeks and capecitabine twice daily on days 8 through 21 of each cycle No treatments will be given during the fourth week of each treatment cycle During the phase I portion of the study patients may receive different doses of capecitabine and paclitaxel since the purpose is to identify the maximum tolerated dose of each drug in combination with carboplatin Once the maximum tolerated dose of these agents is identified during phase I the phase II portion of the study will begin Treatments will be discontinued due to disease growth or unacceptable side effects Several tests and exams will be given throughout the study to closely monitor patients
Purpose The phase I portion of this study will evaluate the maximum tolerated dose of capecitabine and paclitaxel in combination with carboplatin for patients The phase II portion of this study will assess the objective response rate in patients using the same treatment combination Toxicities will be closely measured in both phases of the study
Treatment Patients in this study will be given capecitabine carboplatin and paclitaxel Capecitabine will be given through oral pills Carboplatin and paclitaxel will be given through intravenous infusions Treatment drugs will be given on a four-week cycle Carboplatin will be administered on day 1 paclitaxel weekly for the first 3 weeks and capecitabine twice daily on days 8 through 21 of each cycle No treatments will be given during the fourth week of each treatment cycle During the phase I portion of the study patients may receive different doses of capecitabine and paclitaxel since the purpose is to identify the maximum tolerated dose of each drug in combination with carboplatin Once the maximum tolerated dose of these agents is identified during phase I the phase II portion of the study will begin Treatments will be discontinued due to disease growth or unacceptable side effects Several tests and exams will be given throughout the study to closely monitor patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2011-03593 | REGISTRY | Clinical Trials Reporting Program | None |